Research
Hormonal
GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors (e.g., Empagliflozin, Canagliflozin) significantly reduce cardiovascular risk and mortality in type 2 diabetic patients with high cardiovascular risk factors.
For T2D patients with high cardiovascular risk, GLP-1 receptor agonists (Semaglutide, Liraglutide) and SGLT-2 inhibitors (Empagliflozin, Canagliflozin) are superior to standard treatments for preventing heart attacks, strokes, and cardiovascular death. These drugs offer significant mortality benefits.
StrongSupportsVERY_HIGH confidence
SUSTAIN 6, LEADER和EMPA-REG 研究证实了, 索马鲁肽、利拉鲁肽、恩格列净和坎格列净对伴有心血管高危因素的T2DM患者具有心血管获益.
Why this rating
Based on multiple large-scale, multi-center, randomized, double-blind, placebo-controlled trials (SUSTAIN-6, LEADER, EMPA-REG).
Source
Advances in treatment of obesity-related type 2 diabetes
Dajin Zou · Scientia Sinica Vitae · 2018
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →